Title of article :
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
Author/Authors :
G Comi، نويسنده , , pulizzi، N نويسنده Department of Endocrinology and Metabolism pulizzi, N , M Rovaris، نويسنده , , O Abramsky، نويسنده , , T Arbizu، نويسنده , , A Boiko، نويسنده , , R Gold، نويسنده , , E Havrdova، نويسنده , , Samuel Komoly، نويسنده , , KW Selmaj، نويسنده , , B Sharrack، نويسنده , , M Filippi، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2008
Pages :
8
From page :
2085
To page :
2092
Abstract :
Background A 24-week phase II trial has shown that 0•3 mg of laquinimod given daily to patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions. We assessed the effect of oral daily 0•3 and 0•6 mg
Journal title :
The Lancet
Serial Year :
2008
Journal title :
The Lancet
Record number :
593048
Link To Document :
بازگشت